Moderna (MRNA) Change in Accured Expenses (2018 - 2026)

Moderna (MRNA) has reported Change in Accured Expenses for 9 consecutive years, with $11.0 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Change in Accured Expenses rose 178.57% year-over-year to $11.0 million in Q2 2026; TTM through Jun 2026 was $864.0 million, a 373.42% increase from a year earlier, with the FY2025 full-year figure at -$6.0 million, up 98.44% from the prior year.
• Change in Accured Expenses was $11.0 million for Q2 2026 at Moderna, down from $464.0 million in the prior quarter.
• Over five years, Change in Accured Expenses peaked at $696.0 million in Q3 2023 and troughed at -$1.1 billion in Q4 2022.
• A 5-year average of -$55.3 million and a median of $20.5 million in 2024 frame the typical range for Change in Accured Expenses.
• The widest YoY moves for Change in Accured Expenses: up 1320.41% in 2023, down 534.21% in 2023.
• Over 5 years, Change in Accured Expenses stood at -$1.1 billion in 2022, then surged by 63.16% to -$403.0 million in 2023, then surged by 107.44% to $30.0 million in 2024, then surged by 533.33% to $190.0 million in 2025, then tumbled by 94.21% to $11.0 million in 2026.
• The last three Change in Accured Expenses figures came in at $11.0 million (Q2 2026), $464.0 million (Q1 2026), and $190.0 million (Q4 2025), per Business Quant data.